WO2005042022A3 - Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist - Google Patents

Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist Download PDF

Info

Publication number
WO2005042022A3
WO2005042022A3 PCT/IB2004/003444 IB2004003444W WO2005042022A3 WO 2005042022 A3 WO2005042022 A3 WO 2005042022A3 IB 2004003444 W IB2004003444 W IB 2004003444W WO 2005042022 A3 WO2005042022 A3 WO 2005042022A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
activator
combination
receptor antagonist
cyclase
Prior art date
Application number
PCT/IB2004/003444
Other languages
French (fr)
Other versions
WO2005042022A2 (en
Inventor
David Nathan Abraham Fox
Eric Karran
Original Assignee
Pfizer Ltd
David Nathan Abraham Fox
Eric Karran
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, David Nathan Abraham Fox, Eric Karran, Pfizer filed Critical Pfizer Ltd
Publication of WO2005042022A2 publication Critical patent/WO2005042022A2/en
Publication of WO2005042022A3 publication Critical patent/WO2005042022A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combination comprising a) an activator of soluble guanylate cyclase and b) and angiotensin II receptor antagonist (ARB) are useful for treating hypertension.
PCT/IB2004/003444 2003-10-29 2004-10-20 Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist WO2005042022A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0325291.3 2003-10-29
GBGB0325291.3A GB0325291D0 (en) 2003-10-29 2003-10-29 Novel combination

Publications (2)

Publication Number Publication Date
WO2005042022A2 WO2005042022A2 (en) 2005-05-12
WO2005042022A3 true WO2005042022A3 (en) 2005-08-04

Family

ID=29725605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003444 WO2005042022A2 (en) 2003-10-29 2004-10-20 Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist

Country Status (2)

Country Link
GB (1) GB0325291D0 (en)
WO (1) WO2005042022A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7237823B2 (en) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Combinations comprising SGC activators and mineralocorticoid receptor antagonists

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005047946A1 (en) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Use of soluble guanylate cyclase activators for the treatment of acute and chronic lung diseases
ATE526963T1 (en) 2006-05-04 2011-10-15 Lek Pharmaceuticals PHARMACEUTICAL COMPOSITION CONTAINING OLMESARTAN-MEDOXOMIL
WO2008001734A1 (en) * 2006-06-27 2008-01-03 Daiichi Sankyo Company, Limited Compressed preparation
DE102006031175A1 (en) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Aqueous drug formulation of 4 - [((4-carboxybutyl) - (2 [(4-phenethyl-benzyl) oxy] -phenethyl) amino) methyl] benzoic acid
EP3525779A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc stimulators and mineralocorticoid receptor antagonists
US20190321328A1 (en) * 2016-11-10 2019-10-24 Arena Pharmaceuticals, Inc. Methods of treating pah with combinations of ralinepag and other agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139847A (en) * 1995-06-07 2000-10-31 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6335334B1 (en) * 1998-07-08 2002-01-01 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US20020035067A1 (en) * 1998-08-26 2002-03-21 Adams Michael A. Methods for remodeling neuronal and cardiovascular pathways
WO2002034303A1 (en) * 2000-10-27 2002-05-02 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2003090870A1 (en) * 2002-04-26 2003-11-06 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139847A (en) * 1995-06-07 2000-10-31 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6335334B1 (en) * 1998-07-08 2002-01-01 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
US20020035067A1 (en) * 1998-08-26 2002-03-21 Adams Michael A. Methods for remodeling neuronal and cardiovascular pathways
WO2002034303A1 (en) * 2000-10-27 2002-05-02 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2003090870A1 (en) * 2002-04-26 2003-11-06 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEHRENDS S: "DRUGS THAT ACTIVATE SPEICIFC NITRIC OXIDE SENSITIVE GUANYLYL CYCLASE ISOFORMS INDEPENDENT OF NITRIC OXIDE RELEASE", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 10, no. 4, February 2003 (2003-02-01), pages 291 - 301, XP009038710, ISSN: 0929-8673 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7237823B2 (en) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Combinations comprising SGC activators and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
GB0325291D0 (en) 2003-12-03
WO2005042022A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
JO3492B1 (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
AU2003231513A1 (en) Pgd2 receptor antagonist
AU2003269940A8 (en) Systems, methods, and compositions for achieving closure of suture sites
MXPA04000586A (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor.
WO2006023944A3 (en) Pulmonary delivery of inhibitors of phosphodiesterase type 5
ZA200200596B (en) Method of treating certain cancers using an estrogen agonist/antagonist.
IL166788A (en) Procedure for jammer detection
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
EP1192945A3 (en) Use of an estrogen agonist/antagonist for treating osteoarthritis
IL175292A0 (en) Pharmaceutical composition, containing a beta-3- adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
WO2005042022A3 (en) Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
MY133625A (en) Peptide deformylase inhibitors
AU2003290735A1 (en) Inhibitors of monoamine uptake
TW200509911A (en) Novel combination
WO2004052919A3 (en) Peptide deformylase inhibitors
WO2005034915A3 (en) Screening method for evaluation of bilayer-drug interaction in liposomal compositions
WO2004002461A3 (en) Combination of pde5 inhibitors with angiotensin ii receptor antagonists
AU2003223634A1 (en) Peptide deformylase inhibitors
WO2005032550A3 (en) Peptide deformylase inhibitors
AU2003252017A8 (en) Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
WO2005005456A3 (en) Peptide deformylase inhibitors
WO2001048483A3 (en) Method for screening of appetite control agents
AU2003219327A1 (en) Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
WO2003020315A1 (en) Medicinal compositions containing angiotensin ii receptor antagonist
PL371016A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase